Megestrol Pharmacenter

Megestrol acetate, the active ingredient in Megestrol Pharmacenter, is a progestin presented as an oral tablet for oral use. It is employed as an appetite stimulant and as a hormonal therapy for certain cancers and for cachexia associated with AIDS or cancer, particularly in palliative care settings.

GNH USA supplies Megestrol Pharmacenter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Megestrol acetate is used in conditions where appetite stimulation or anti‑estrogenic hormonal therapy is required. - Cachexia associated with AIDS: improves appetite and promotes weight gain in patients with AIDS‑related wasting. - Cachexia associated with cancer: helps increase caloric intake and stabilise body weight in oncology patients. - Breast cancer: used as a hormonal agent to treat advanced or recurrent disease. - Endometrial cancer: employed as a progestogenic therapy for certain stages of the disease. - Appetite stimulation: prescribed to enhance food intake in patients with severe weight loss.

Megestrol acetate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Weight gain: increase in body weight due to fluid retention or fat accumulation. - Edema: swelling of the limbs or face. - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes of stomach emptying. - Fatigue: general tiredness or lack of energy. - Hot flashes: transient warmth and sweating.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Hyperglycemia: elevated blood sugar levels, potentially precipitating diabetes. - Adrenal insufficiency: reduced cortisol production on abrupt discontinuation. - Liver dysfunction: abnormal liver enzymes or hepatitis. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Megestrol acetate, clinicians should consider several safety precautions to minimise risk. - Assess baseline weight and nutritional status: evaluate before initiating therapy. - Monitor blood glucose: check fasting glucose periodically, especially in diabetic patients. - Evaluate for thrombotic risk: avoid in patients with history of clotting disorders. - Review liver function tests: perform baseline and periodic LFTs. - Consider adrenal function: taper gradually to prevent insufficiency. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Megestrol acetate can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk due to altered protein binding. - CYP3A4 inducers (e.g., rifampin, phenytoin): can reduce megesterol levels and effectiveness. - Glucocorticoids: concurrent use may exacerbate adrenal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: risk of hyperglycemia may require dose adjustment. - Hormonal therapies (e.g., tamoxifen): may interfere with anti‑estrogenic activity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase megesterol exposure.